1. Medtech Insight
  2. >>Business

Innovator Spotlight: Vertos Plans To Expand Reach Of Minimally Invasive Lumbar Decompression

 
• By Reed Miller

New professional consensus guidelines recommend Vertos Medical’s minimally invasive lumbar decompression (MILD) system as an alternative to epidural steroid injections for patients with lumbar stenosis. The company is planning to raise more capital to expand its commercial operation so it can reach more patients that could benefit from MILD.

Neurological diagnosis of Lumbar Spinal Stenosis. Neurologist directory, where is printed diagnosis Lumbar Spinal Stenosis, lies on workplace with MRI image and neurological diagnostic tools close-up - Image
• Source: shutterstock.com

Vertos Medical Inc. is planning a major commercial expansion by the end of 2019 to support its minimally invasive lumbar decompression (MILD) system to treat lumbar stenosis.

“We are contemplating doing a large expansion to make this procedure available to others,” Vertos CEO Eric Wichems told Medtech Insight. “We're anticipating another injection of money to be able...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.